Table 3.
Parameter | Source (country of origin) |
---|---|
Age-assortative polymod mixing matrix | Mossong et al. [12] (Netherlands) |
Pre-vaccine serotype-specific carriage | Croucher et al. [14] (USA) |
PCV introduction schedule | McLaughlin et al. [16] (USA) |
Vaccine efficacy | • Main study: efficacy data from Dagan et al. [17] (Israel) • Supplemental figures: immunogenicity data from Goldblatt et al. [8, 20] (United Kingdom) |